Aon PLC vs Ginkgo Bioworks Holdings Inc — how do they compare? Aon PLC trades at $351.67 (market cap $75.61B), while Ginkgo Bioworks Holdings Inc trades at $7.46 (market cap $505.73M). The key difference: Aon PLC is far larger — about 149.5× Ginkgo Bioworks Holdings Inc's market cap, and Aon PLC pays a 0.92% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AON | DNA | |
|---|---|---|
Market Cap | $75.61B | $505.73M |
Sector | Financials | Health |
52-Week High | $381.26 | $16.14 |
52-Week Low | $308.22 | $5.48 |
Enterprise Value | $90.22B | $607.68M |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
AON trades at $356.97, down 0.37% with neutral technical signals. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $3.81 versus $3.80 expected, marking the third consecutive quarterly beat. Revenue growth accelerated to 5% organic in Q2 2026, while margins expanded 70 basis points. Analyst consensus price target stands at $410, representing 15% upside potential from current levels.
AON presents a compelling investment case with consistent earnings outperformance and robust profitability metrics including 44.88% ROE. However, premium valuation multiples and modest organic growth create headwinds. The stock offers 15% upside to consensus targets but requires monitoring of valuation compression risks amid competitive insurance brokerage markets.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Trailing returns across standard periods
Latest headlines on both assets
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →